Top of the page
Lung transplant is an option for a few people who have severe lung problems that are caused by a number of diseases: cystic fibrosis, pulmonary fibrosis, emphysema, and pulmonary hypertension to name a few. The procedure removes the diseased lungs and replaces them with healthy lungs from a recently deceased donor.
Sometimes a procedure called a living-donor lobar lung transplant is performed while a person is waiting for a full lung transplant. In this procedure, the lower section (lobe) of one lung in each of two living donors (who may be related or unrelated to the person who has cystic fibrosis) is transplanted into the person who has cystic fibrosis. Because this complicated transplant involves two living donors, it is performed less often than other kinds of lung transplants.
After lung transplant surgery, you will be put on a ventilator, which is a machine that temporarily takes over the breathing process. If there are no complications, you will use the ventilator for 1 to 2 days.
You will likely need to stay in the hospital for 2 to 3 weeks after the transplant.
You'll need to take antibiotics and medicines to suppress your immune system to decrease the chances that your body will reject the donor lungs.
Some people who have severe lung damage may get a lung transplant. In some cases a lung transplant doesn't necessarily help a person live longer, but it hopefully will increase the quality of a person's life.
Several tests can help your doctor and you see how well a lung transplant or a living-donor lobar lung transplant might work. These tests include lung function tests, arterial blood gas tests, and exercise capacity.
The main risks of lung transplant are infection and rejection of the donated organs. Infection and rejection of transplanted organs have similar symptoms, including fever, tiredness, and trouble breathing.
After a lung transplant, preventive antibiotic therapy starts right away. You will also take immunosuppressant medicines for the rest of your life. Although immunosuppressant medicines decrease the chances that your body will reject the donor lungs, they also make it harder for your body to fight off infection.
CitationsLiou TG, et al. (2007). Lung transplantation and survival in children with cystic fibrosis. New England Journal of Medicine, 357(21): 2143–2152. [Erratum in New England Journal of Medicine, 359(e6).]Organ Procurement and Transplantation Network (2017). Kaplan-Meier patient survival rates for transplants performed, 2008-2015. Based on OPTN data as of April 21, 2017. Organ Procurement and Transplantation Network. https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/. Accessed April 26, 2017.
Adaptation Date: 8/19/2021
Adapted By: Alberta Health Services
Adaptation Reviewed By: Alberta Health Services
To learn more about Healthwise, visit Healthwise.org.
© 1995-2021 Healthwise, Incorporated. All rights reserved. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.